"We are going to have lung cancer patients living longer and better:" A new kind of cancer treatment is about to change how we treat the disease (MRK, BMS)

Novartis AG said late Friday the U.S. Food and Drug Administration has approved one of its treatments for a type of advanced breast cancer afflicting patients carrying a gene.....»»

Brainstorm Health Daily: May 20, 2019 Happy Monday, readers! I hope you enjoyed your weekend. The machines just aced a major test in the world of cancer detection. A joint collaborati.....»»

Cancer is the second leading cause of death worldwide. About 9.6 million people died from the disease last year, according to the World Health Organization — about one in every six deaths. In........»»

Cancer is the second leading cause of death worldwide. About 9.6 million people died from the disease last year, according to the World Health Organization — about one in every six deaths. In........»»

Cancer is the second leading cause of death worldwide. About 9.6 million people died from the disease last year, according to the World Health Organization — about one in every six deaths. In........»»

AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial......»»

Shares of Puma Biotechnology Inc. fell nearly 33% Thursday after the biotech company reported a narrower-than-expected first-quarter loss and sales that beat expectations, but said net product revenue, ce.....»»

Merck & Co. Inc. said Friday that a Phase 3 trial evaluating Keytruda as a first-line treatment for gastric cancer failed to show improvement in patients' overall or progression-free survival when compared with chemotherapy. Shares of th.....»»

Johnson & Johnson beat quarterly profit estimates on Tuesday and raised its adjusted sales growth forecast for the year, driven by demand for its treatment for psoriasis and Crohn's disease and cancer drugs Darzalex and Imbruvica......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer po.....»»

Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resista.....»»

The Universal Cancer Databank will allow patients with rare cancers to share their data anonymously with researchers and other patients around the world using individual genome sequencing and profiling......»»

Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates......»»

Combining expensive cancer immunotherapies with each other or with older drugs prolonged survival in lung cancer patients, two studies show. But the costs are high......»»

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

The pairing of Keytruda and chemotherapy reduced risk of death for patients with advanced lung cancer by half, a significant improvement......»»

Reuters On Monday, three big players in the growing field of cance.....»»

Merck gained.....»»

Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint......»»